The IRL Team has created the Integrative Screening Process, an efficient platform for generation of innovations within the CNS research field. ISP is based on phenotypic screening and systems pharmacology, systematically implemented and seamlessly integrated throughout the drug discovery process. The unique philosophy behind ISP leads to high precision, i.e. minimal risk of taking compounds with undesired properties to clinical trials, and low risk of overlooking compounds with potentially valuable effects.

ISP relies on the principle of mapping the overall physiological effect in response to treatment, in the healthy state and in models of disease. Such in vivo mapping combined with medicinal chemistry is used to derive novel treatment principles and compounds.

ISP is based on studies of physiological and pathophysiological mechanisms at the system level in the living brain and the effects of drugs and drug candidates on these mechanisms at the integrated level. A screening system is built on in vivo systems responses, combined with strong medicinal chemistry programmes.

IRLs extensive database covering systems response profiles of a growing library of compounds with documented CNS effects in humans enable comparisons, classifications and facilitate translational efforts to predict clinical effects.

The decision model of ISP can be described as an integrative and parallel decision model in contrast to the binary and sequential model prevailing in the industry today.